Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02678325
Other study ID # 2016-00041
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date May 21, 2016
Est. completion date December 31, 2019

Study information

Verified date March 2021
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to compare the difference in daily protein intake of critically ill patients in two standardized enteral nutrition formulas (20% versus 33% percent) with the same caloric density of 1.2 kcal/ml. The total amount of protein taken in on day four after starting the early enteral feeding is defined as primary endpoint.


Description:

For years, the Surgical Intensive Care Unit of the University Hospital Basel has used an early enteral approach for the feeding of critically ill patients with different formulas that have high protein content (20% of total energy). However, the energy goal in the first week is only 20 kcal for normal-weight and 12.5 kcal for obese patients, which results in daily protein amounts of 0.8 to 1 g/kg bodyweight (BW), so that additional protein has to be administered. Due to a suggestion of the dietetic service of the University Hospital Basel, Fresenius Kabi produced a whey based enteral feeding formula for intensive care patients. Specific further adaptations for this patient group included micronutrients and a fatty acid profile as well as low fibres. Surgical Intensive Care Unit of the University Hospital Basel now are offered the opportunity to test this formula in clinical practice and hypothesize that this specific high-protein (30% of energy) enteral formula reaches the same amount of daily caloric intake with a higher total daily amount of protein and equal intestinal tolerance compared to a usual intestinal nutritional formula. In order to test this hypothesis, investigators plan a double-blind, randomized and controlled study with the aim to achieve a target protein quantity of ≥1.3 g/kg BW with an energy target of 20kcal/kg BW per day, based on a new, specifically designed formula for critically ill patients. The amount of protein on day four after starting the early enteral feeding is defined as primary endpoint. Secondary endpoints are the total amount of calories, the nitrogen balance on day five as well as side effects like gastric residual content, diarrhoea and constipation. Inclusion criteria were an expected stay at the ICU of four days or longer on admission and 18 years of age or older Exclusion criteria consisted of BMI ≤ 18, pregnancy, intestinal perforation, mechanical intestinal obstruction, terminal state of consuming disease, severely impaired liver function and noradrenaline ≥0.5µg/kg BW/min.. On this purpose, 90 critically ill patients will get either of the two enteral feeding products as described above. In case of the event that an increased protein intake can be obtained by the protein-rich formula, an additional study will investigate the influence of early protein-rich nutrition on skeletal muscle wasting with critically ill patients. In a pre-study investigators will administer the high protein formula to 20 patients to test tolerance and suitability for the nutritional Targets in question. Tolerance will be defined by the absence of one of the following clinical symptoms : - Reflux - Diarrhoea - Constipation - Nausea - Vomiting


Recruitment information / eligibility

Status Terminated
Enrollment 25
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients (age 18 years or older) - expected stay at the ICU of four days upon admittance or longer - expected enteral feeding during at least four days. Exclusion Criteria: - BMI = 18 - Mechanical intestinal obstruction - Intestinal perforation - Severely impaired liver function - Terminal state of consuming disease - Noradrenaline =0.5µg/kg BW/min - Pregnancy

Study Design


Intervention

Other:
Standardized high protein enteral nutrition
A double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration on muscle breakdown and mortality.
Standardized normal protein enteral nutrition
double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration (compared to normal enteral protein administration) on muscle breakdown and mortality.

Locations

Country Name City State
Switzerland University Hospital Basel Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary The amount of protein The amount of protein administered on day four after starting the early enteral feeding. 4 days
Secondary The total amount of calories Indirect Calorimetry 4 days
Secondary The nitrogen balance on day four Nitrogen input - nitrogen loss measured over 4 days 4 days
Secondary Gastric residual Content in ml ml 4 days
Secondary Number of diarrhea events Number 4 days
Secondary occurence of constipation as measured in time without defecation time frame without defecation 4 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05817448 - Hypoxia-induced Autophagy in the Pathogenesis of MAP
Not yet recruiting NCT05524376 - Regulatory Network and Diagnostic Value of Key Autophagy-related Genes in Sepsis
Recruiting NCT04160455 - Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.
Withdrawn NCT04842864 - Time Course for Fasting-induced Autophagy in Humans N/A
Active, not recruiting NCT06115551 - Fasting Mimicking Diet and Autophagy N/A
Completed NCT03925753 - Correlation Between Autophagy-related Proteins and Inflammatory Markers in Hemodialysis Patients
Completed NCT04706000 - Autophagy Markers in Endometrial Polyps
Recruiting NCT03371758 - Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo N/A
Completed NCT03267160 - A Study of Exosome Proteomics and Hemodynamics in Sepsis
Recruiting NCT05279638 - ATG5 as a Serum Marker of Autophagy in Psoriatic Patient